BAP increased dose dependently with RSV ( R = 0.471 , P < .001 ) , resulting in a significantly greater increase in BAP in the RSV ( high ) group compared with placebo at all time-points ( week 4 , 16.4 4.2 % , P < .001 ; week 8 , 16.5 4.1 % , P < .001 ; week 16 , 15.2 3.7 % , P < .001 ) .